the tape · 2026-08-21COIN▲ +8.2%FCX▲ +7.6%MRVL▼ -5.6%TSLA▲ +5.1%GS▲ +3.7%PLTR▲ +3.4%MS▲ +3.3%ORCL▲ +3.1%NEM▲ +3.1%ARM▼ -3.0%MRK▲ +2.4%INTC▼ -2.2%SPCX▲ +2.2%ABT▲ +2.2%SMCI▲ +2.0%VST▼ -2.0%DLR▼ -1.9%CRM▲ +1.8%PM▼ -1.7%DELL▲ +1.7%
LLY
Eli Lilly ·
32 big moves · 1 videos · since May 2026
From the desk · Aug 19, 2026
Eli Lilly jumped 4.5 percent today — no single press release drove it, but Novo Nordisk's 'best value in pharma' narrative is clearly not sticking with the institutional crowd. When an analyst publishes that argument about a competitor, traders often put on the opposite side. The fundamental anchor is Lilly's tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — which has been outpacing semaglutide on head-to-head weight loss outcomes. That efficacy lead is what keeps buyers coming back to LLY even on quiet days. The real story embedded in Lilly's valuation is orforglipron, the company's oral GLP-1 pill. An oral in this category changes the whole addressable market — it's not just a convenience upgrade, it's a manufacturing and distribution unlock. That's the move worth modeling.
Every move of 1.5% or more
2026-08-20 · no single source
-2.8% — Moved with the tape — no single reported reason that day.
T+1 +0.9%T+5 — pendingT+20 — pending
2026-08-19 · Benzinga
+4.5% — Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’
T+1 -2.8%T+5 — pendingT+20 — pending
2026-08-18 · SeekingAlpha
+3.6% — OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
T+1 +4.5%T+5 — pendingT+20 — pending
2026-08-14 · Yahoo
-2.4% — 5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
T+1 +0.3%T+5 +6.4%T+20 — pending
2026-08-10 · Yahoo
+3.9% — Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
T+1 -1.4%T+5 -4.0%T+20 — pending
2026-08-06 · SeekingAlpha
+1.9% — Eli Lilly: Fine Q2 2026 Results, But Alertness Required
T+1 -0.5%T+5 +1.4%T+20 — pending
2026-08-05 · Yahoo
+4.9% — Eli Lilly and Co (LLY) (Q2 2026) Earnings Call Highlights: Revenue Surges 48% on Zepbound and ...
T+1 +1.9%T+5 +4.3%T+20 — pending
2026-08-03 · Yahoo
-2.4% — Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Backs $70 Million Raise
T+1 -0.5%T+5 +9.9%T+20 — pending
2026-07-30 · Yahoo
-4.5% — Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
T+1 -0.5%T+5 +3.2%T+20 — pending
2026-07-28 · Yahoo
+1.9% — Does Eli Lilly Stock Actually Diversify Your Portfolio?
T+1 -0.9%T+5 -8.6%T+20 — pending
2026-07-23 · Yahoo
+2.0% — There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders
T+1 +0.9%T+5 -2.6%T+20 +4.9%
2026-07-21 · Yahoo
+2.5% — "Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What Tha
T+1 -1.1%T+5 +3.8%T+20 +4.3%
2026-07-20 · Yahoo
-2.7% — Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?
T+1 +2.5%T+5 +4.4%T+20 +3.2%
2026-07-14 · Yahoo
-2.5% — Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors
T+1 +0.4%T+5 +2.0%T+20 +5.4%
2026-07-10 · Benzinga
-2.3% — B of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1334
T+1 -0.6%T+5 -0.8%T+20 -0.2%
2026-07-07 · Yahoo
+3.0% — Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 B
T+1 -1.6%T+5 -6.7%T+20 -9.7%
2026-07-02 · Yahoo
+1.9% — Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
T+1 -1.1%T+5 -2.1%T+20 -5.4%
2026-06-30 · Yahoo
-2.5% — Medicare GLP-1 Bridge Program Will Pay for Novo, Lilly Drugs
T+1 -0.6%T+5 +1.4%T+20 +0.9%
2026-06-29 · Yahoo
+1.8% — Should You Chase The Breakout In Eli Lilly Stock?
T+1 -2.5%T+5 +0.5%T+20 -0.8%
2026-06-26 · Yahoo
+7.1% — Lilly, J&J and AbbVie Hit New Highs ▶ we covered it
T+1 +1.8%T+5 -0.7%T+20 -0.9%
2026-06-12 · no single source
-2.4% — Moved with the tape — no single reported reason that day.
T+1 -0.3%T+5 -2.7%T+20 +1.7%
2026-06-11 · no single source
+2.2% — Moved with the tape — no single reported reason that day.
T+1 -2.4%T+5 -5.4%T+20 +1.8%
2026-06-08 · no single source
+1.6% — Moved with the tape — no single reported reason that day.
T+1 -0.4%T+5 -1.7%T+20 +5.8%
2026-06-04 · no single source
+4.3% — Moved with the tape — no single reported reason that day.
T+1 +0.5%T+5 +3.2%T+20 +6.6%
2026-06-02 · no single source
-1.7% — Moved with the tape — no single reported reason that day.
T+1 +1.4%T+5 +7.6%T+20 +12.0%
2026-06-01 · no single source
-2.1% — Moved with the tape — no single reported reason that day.
T+1 -1.7%T+5 +6.2%T+20 +10.8%
2026-05-29 · no single source
-1.9% — Moved with the tape — no single reported reason that day.
T+1 -2.1%T+5 +2.4%T+20 +11.3%
2026-05-28 · no single source
+4.1% — Moved with the tape — no single reported reason that day.
T+1 -1.9%T+5 -0.1%T+20 +7.2%
2026-05-27 · Yahoo
+1.7% — Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?
T+1 +4.1%T+5 -0.4%T+20 +4.1%
2026-05-22 · no single source
+2.2% — Moved with the tape — no single reported reason that day.
T+1 -0.0%T+5 +1.6%T+20 +4.0%
2026-05-21 · no single source
+2.2% — Moved with the tape — no single reported reason that day.
T+1 +2.2%T+5 +6.1%T+20 +5.8%
The brief, in your inbox
One email every market morning. What moved, why, and what happened after.